Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 1/20 | 0.38 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.36 |
| ▸ | FABP7 | O15540 | 2/20 | 0.36 |
| ▸ | MDM4 | O15151 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25657528 | 0.88 | KMT2A (0.39) | MDM2KMT2AFABP5FABP7EPHX2 | |
| SCHEMBL22091999 | 0.86 | KMT2A (0.47) | MDM2KMT2AFABP5FABP7EPHX2 | |
| SCHEMBL30278742 | 0.86 | KMT2A (0.47) | MDM2KMT2AFABP5FABP7EPHX2 | |
| SCHEMBL25657526 | 0.86 | KMT2A (0.40) | MDM2KMT2AFABP5FABP7EPHX2 | |
| SCHEMBL25112440 | 0.85 | KMT2A (0.40) | KMT2AFABP5FABP7EPHX2 | |
| SCHEMBL30510339 | 0.85 | KMT2A (0.42) | KMT2AFABP5FABP7EPHX2 | |
| SCHEMBL21837525 | 0.85 | KMT2A (0.42) | KMT2AFABP5FABP7EPHX2 | |
| SCHEMBL27032721 | 0.85 | FABP5 (0.38) | MDM2KMT2AFABP5FABP7EPHX2 | |
| SCHEMBL22092037 | 0.85 | KMT2A (0.39) | CASRMDM2KMT2AFABP5FABP7 | |
| SCHEMBL25657525 | 0.85 | KMT2A (0.37) | MDM2KMT2AFABP5FABP7EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118256591-A | Cyclic peptide compound having high membrane permeability and library comprising same | 中外制药株式会社 | 2024-06-28 | — | — | CN | disclosed |
| CN-110869544-B | Cyclic peptide compound having high membrane permeability and library comprising same | 中外制药株式会社 | 2024-03-08 | — | — | CN | disclosed |
| US-20200131669-A1 | CYCLIC PEPTIDE COMPOUND HAVING HIGH MEMBRANE PERMEABILITY, AND LIBRARY CONTAINING SAME | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2020-04-30 | — | — | US | disclosed |
| EP-3636807-A1 | CYCLIC PEPTIDE COMPOUND HAVING HIGH MEMBRANE PERMEABILITY, AND LIBRARY CONTAINING SAME | Chugai Seiyaku Kabushiki Kaisha (JP) | 2020-04-15 | — | — | EP | disclosed |
| CN-110869544-A | Cyclic peptide compound having high membrane permeability and library containing same | 中外制药株式会社 | 2020-03-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200131669-A1 | CYCLIC PEPTIDE COMPOUND HAVING HIGH MEMBRANE PERMEABILITY, AND LIBRARY CONTAINING SAME | VIP, SLC7A1, TRPV1 | CASR 843/4885MDM2 3434/4885KMT2A 4201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.